Ginkgo Bioworks Holdings, Inc.
NYSEGinkgo Bioworks heads into the back half of 2026 with a fresh downgrade, rising short interest, and a peer group that largely left it behind this week. The analyst shift is the week's clearest development. TD Cowen's Brendan Smith downgraded Ginkgo to Hold from Buy on August 7, cutting his price target from $12 to $9 — and the stock at $7.97 is already trading through that new…
Snapshot as of 8 Aug 2026
Ginkgo Bioworks heads into the back half of 2026 with a fresh downgrade, rising short interest, and a peer group that largely left it behind this week. The analyst shift is the week's clearest development. TD Cowen's…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DNA — free to start on ORTEX.
Sign up for free →Open DNA on ORTEX